State-of-the-art issues in Hodgkin's lymphoma survivorship.
The prognosis of Hodgkin's lymphoma (HL) has markedly improved as management strategies evolved. In the modern era, less than 15% of patients with early-stage, non-bulky HL will relapse, and less than one third of those with advanced disease will relapse. As therapy for HL intensified, and as disease-related outcomes improved, the impact of the late effects of therapy has become increasingly important. There is a growing body of literature describing the late morbidity experienced by survivors of HL, including risks of second primary malignancy, cardiac disease, pulmonary disease, and endocrine dysfunction. Additionally, the impact of disease and treatment on psychosocial function and quality of life has been a subject of investigation, with survivors often suffering from impairment. An understanding of these risks and the management implications inherent to them is central to the care of survivors of HL.
Baxi
Shrujal S
SS
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Matasar
Matthew J
MJ
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002318:Cardiovascular Diseases / Q000209:etiology; D003131:Combined Modality Therapy; D004700:Endocrine System Diseases / Q000209:etiology; D005260:Female; D006689:Hodgkin Disease / Q000150:complications / Q000401:mortality / Q000473:pathology* / Q000523:psychology / Q000628:therapy*; D006801:Humans; D008171:Lung Diseases / Q000209:etiology; D008297:Male; D009017:Morbidity; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000401:mortality; D011379:Prognosis; D011788:Quality of Life; D015996:Survival Rate
D000970:Antineoplastic Agents